These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3799661)

  • 1. Kinetics and dynamics of nifedipine after oral and sublingual doses.
    McAllister RG
    Am J Med; 1986 Dec; 81(6A):2-5. PubMed ID: 3799661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Negligible sublingual absorption of nifedipine.
    van Harten J; Burggraaf K; Danhof M; van Brummelen P; Breimer DD
    Lancet; 1987 Dec; 2(8572):1363-5. PubMed ID: 2890954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study of buccoadhesive formulations and sublingual capsules of nifedipine.
    Save T; Shah MU; Ghamande AR; Venkitachalam P
    J Pharm Pharmacol; 1994 Mar; 46(3):192-5. PubMed ID: 8027926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the method for nifedipine administration for a rapid onset of clinical effect: a clinical study in normal volunteers.
    Kubota R; Komiyama T; Shimada H
    Yakugaku Zasshi; 2001 May; 121(5):355-64. PubMed ID: 11360489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nifedipine serum concentrations following sublingual and oral doses.
    Brown GR; Fraser DG; Castile JA; Gaudreault P; Platt DR; Friedman PA
    Int J Clin Pharmacol Ther Toxicol; 1986 Jun; 24(6):283-6. PubMed ID: 3733277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-bioequivalence of sublingual nifedipine.
    Rietbrock N; Kausch M; Engelhardt M; Woodcock BG
    Br J Clin Pharmacol; 1987 May; 23(5):589-90. PubMed ID: 3593629
    [No Abstract]   [Full Text] [Related]  

  • 7. Nifedipine: kinetics and dynamics in healthy subjects.
    Kleinbloesem CH; van Brummelen P; van de Linde JA; Voogd PJ; Breimer DD
    Clin Pharmacol Ther; 1984 Jun; 35(6):742-9. PubMed ID: 6734025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration.
    Kleinbloesem CH; van Harten J; Wilson JP; Danhof M; van Brummelen P; Breimer DD
    Clin Pharmacol Ther; 1986 Jul; 40(1):21-8. PubMed ID: 3720176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sublingual nifedipine: the continuing controversy.
    Oliver S
    Aust Crit Care; 1994 Jun; 7(2):12-4. PubMed ID: 8061479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of sublingual captopril and nifedipine in immediate treatment of hypertensive emergencies. A randomized, single-blind clinical trial.
    Angeli P; Chiesa M; Caregaro L; Merkel C; Sacerdoti D; Rondana M; Gatta A
    Arch Intern Med; 1991 Apr; 151(4):678-82. PubMed ID: 2012448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the acute hypotensive effects of two different doses of nifedipine.
    Maharaj B; van der Byl K
    Am Heart J; 1992 Sep; 124(3):720-5. PubMed ID: 1514500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship.
    Kleinbloesem CH; van Brummelen P; van Harten J; Danhof M; Breimer DD
    Clin Pharmacol Ther; 1985 May; 37(5):563-74. PubMed ID: 3987180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of conventional and slow release forms of nifedipine in essential hypertensive patients.
    Imai Y; Abe K; Sasaki S; Nihei M; Sekino H; Yoshinaga K
    Tohoku J Exp Med; 1986 Apr; 148(4):421-38. PubMed ID: 3738908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of sublingual verapamil in patients with severe essential hypertension: comparison with sublingual nifedipine.
    Al-Waili NS; Hasan NA
    Eur J Med Res; 1999 May; 4(5):193-8. PubMed ID: 10336409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discrepancy between Bioavailability and Hypotensive Effect of Oral and Sublingual Nifedipine.
    Palma-Aguirre JA; Montoya-Cabrera MA; du Souich P; Hoyo-Vadillo C; Flores-Murrieta FJ; Castañeda-Hernández G
    Am J Ther; 1995 Jan; 2(1):3-9. PubMed ID: 11850640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Gastric Fluid Volume on the In Vitro Dissolution and In Vivo Absorption of BCS Class II Drugs: a Case Study with Nifedipine.
    Nader AM; Quinney SK; Fadda HM; Foster DR
    AAPS J; 2016 Jul; 18(4):981-8. PubMed ID: 27106837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects.
    Foster TS; Hamann SR; Richards VR; Bryant PJ; Graves DA; McAllister RG
    J Clin Pharmacol; 1983 Apr; 23(4):161-70. PubMed ID: 6863580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of nifedipine absorption from soft gelatin capsules using PBPK modeling and biorelevant dissolution testing.
    Thelen K; Jantratid E; Dressman JB; Lippert J; Willmann S
    J Pharm Sci; 2010 Jun; 99(6):2899-904. PubMed ID: 20014280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and metabolism of nifedipine.
    Raemsch KD; Sommer J
    Hypertension; 1983; 5(4 Pt 2):II18-24. PubMed ID: 6862586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is sublingual nifedipine administration superior to oral administration in the active treatment of hypertension?
    Diker E; Ertürk S; Akgün G
    Angiology; 1992 Jun; 43(6):477-81. PubMed ID: 1595942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.